Cargando…
Design, Synthesis and Structure-activity Studies of Rhodanine Derivatives as HIV-1 Integrase Inhibitors
Raltegravir was the first HIV-1 integrase inhibitor that gained FDA approval for use in the treatment of HIV-1 infection. Because of the emergence of IN inhibitor-resistant viral strains, there is a need to identify innovative second-generation IN inhibitors. Previously, we identified 2-thioxo-4-thi...
Autores principales: | Ramkumar, Kavya, Yarovenko, Vladimir N., Nikitina, Alexandra S., Zavarzin, Igor V., Krayushkin, Mikhail M., Kovalenko, Leonid V., Esqueda, Adrian, Odde, Srinivas, Neamati, Nouri |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6264390/ https://www.ncbi.nlm.nih.gov/pubmed/20657419 http://dx.doi.org/10.3390/molecules15063958 |
Ejemplares similares
-
Raltegravir, elvitegravir, and metoogravir: the birth of "me-too" HIV-1 integrase inhibitors
por: Serrao, Erik, et al.
Publicado: (2009) -
Raltegravir, elvitegravir, and metoogravir: the birth of "me-too" HIV-1 integrase inhibitors
por: Serrao, Erik, et al.
Publicado: (2009) -
Synthesis of (2-chloroquinolin-3-yl)-1,3,4-thiadiazole-2-carboxamides
por: Aksenov, A. N., et al.
Publicado: (2021) -
Raltegravir: The evidence of its therapeutic value in HIV-1 infection
por: Ramkumar, Kavya, et al.
Publicado: (2010) -
Integrin Targeted Therapeutics
por: Millard, Melissa, et al.
Publicado: (2011)